A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Launched by BRISTOL-MYERS SQUIBB · Oct 10, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant must be of Japanese ethnicity (both biological parents are ethnically Japanese) for Part 1 and Part 2, Panel 2. No limitations on ethnicity apply to Part 2, Panel 1
• • Participant is healthy, without any significant abnormalities in medical history, physical examination, ECGs, or clinical laboratory assessments determinations, as assessed by the investigator
• • Body mass index (BMI) of at least 18 kg/m\^2 but no more than 32 kg/m\^2 at screening
• • Body weight between 45 kg and 110 kg
• Exclusion Criteria:
• • Any clinically significant deviation from normal, as judged by the investigator
• • Any major surgery within 90 days of study drug administration
• • Participation in another interventional clinical trial concurrent with this study
• • Note: Other protocol-defined inclusion/exclusion criteria apply